Enhancing oncolytic virotherapy of glioblastoma by targeting innate immune ligands with a bispecific T cell engager
<p>Glioblastoma (GBM) is a highly aggressive brain tumour in adults, often becoming resistant towards conventional therapy of radiotherapy and temozolomide (TMZ) chemotherapy. The oncolytic herpes simplex virus-1 (oHSV- 1) G207 is a promising approach for GBM immunotherapy, capable of selectiv...
Main Author: | Baugh, R |
---|---|
Other Authors: | Seymour, L |
Format: | Thesis |
Language: | English |
Published: |
2022
|
Subjects: |
Similar Items
-
From Benchtop to Bedside: A Review of Oncolytic Virotherapy
by: Audrey H. Choi, et al.
Published: (2016-08-01) -
The Continued Promise and Many Disappointments of Oncolytic Virotherapy in Gastrointestinal Malignancies
by: Daniel H. Ahn, et al.
Published: (2017-03-01) -
Delivery and Biosafety of Oncolytic Virotherapy
by: Lizhi Li, et al.
Published: (2020-04-01) -
Current Status and Challenges of Oncolytic Virotherapy for the Treatment of Glioblastoma
by: Mason J. Webb, et al.
Published: (2023-05-01) -
Combining of Oncolytic Virotherapy and Other Immunotherapeutic Approaches in Cancer: A Powerful Functionalization Tactic
by: Hai Zou, et al.
Published: (2023-01-01)